Pipeline

Candidate

Indication

Preclinical

Phase 1

Phase 2

Phase 3

CT1812

Mild-to-Moderate Alzheimer's Disease

SHINE and SEQUEL Studies Ongoing

CT1812

Early-stage Alzheimer's Disease

In Collaboration with the Alzheimer's Clinical Trials Consortium (ACTC)

CT1812

Dementia with Lewy Bodies

Phase 2 initiation 2H 2021*

CT1812

Dry Age-related Macular Degeneration

Phase 2 initiation 2H 2021*

CT2168

Synucleinopathies

Including Parkinson's disease and DLB

CT2074

Dry Age-related Macular Degeneration

* Subject to discussion with FDA, the clinical development programs will begin with Phase 2 studies supported by the Phase 1 AD studies

Disruptions in Cellular Damage Response Drive Neurodegenerative Diseases
Alzheimer’s and Parkinson’s diseases and other neurodegenerative brain and eye disorders are caused by the age-related buildup of proteins such as beta amyloid (Aβ) and α-synuclein. Under normal conditions, cellular damage responses trigger the removal of these proteins before they are allowed to accumulate and aggregate into more toxic forms. However, in many neurodegenerative diseases, the damage response is disrupted, allowing the formation of toxic proteins, which in turn leads to damage and eventual loss of the neurons responsible for cognition in Alzheimer’s disease, cognitive and motor function in Parkinson’s disease, and sight in dry AMD.
Lead Candidate:
CT1812

Cognition has identified several compounds that bind to a receptor that regulates the cellular damage response and have shown potential in the treatment of Alzheimer’s and Parkinson’s diseases. The company’s lead candidate, CT1812, is a first-in-class, orally dosed and highly brain penetrant small molecule that is being assessed as a treatment for mild-to-moderate Alzheimer’s disease. Several studies designed to assess the safety, efficacy and mechanism of action of CT1812 are underway and planned.

Beginning in 2021, Cognition intends to study CT1812 in indications beyond Alzheimer’s disease, including dry AMD.

Scroll to Top